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ABSTRACT: The effectiveness of β-lactam antibiotics is increas-
ingly compromised by β-lactamases. Boron-containing inhibitors
are potent serine-β-lactamase inhibitors, but the interactions of
boron-based compounds with the penicillin-binding protein (PBP)
β-lactam targets have not been extensively studied. We used high-
throughput X-ray crystallography to explore reactions of a boron-
containing fragment set with the Pseudomonas aeruginosa PBP3
(PaPBP3). Multiple crystal structures reveal that boronic acids
react with PBPs to give tricovalently linked complexes bonded to
Ser294, Ser349, and Lys484 of PaPBP3; benzoxaboroles react with
PaPBP3 via reaction with two nucleophilic serines (Ser294 and
Ser349) to give dicovalently linked complexes; and vaborbactam
reacts to give a monocovalently linked complex. Modifications of
the benzoxaborole scaffold resulted in a moderately potent inhibition of PaPBP3, though no antibacterial activity was observed.
Overall, the results further evidence the potential for the development of new classes of boron-based antibiotics, which are not
compromised by β-lactamase-driven resistance.
■ INTRODUCTION
β-Lactam antibacterials, that is, penicillins, carbapenems,
monobactams, and cephalosporins, target the penicillin-bind-
ing protein (PBP) family of transpeptidases. In Gram-negative
bacteria, inhibition of high-molecular mass (HMM) class A
and class B PBPs (PBP1a/b, PBP2, and PBP3) is typically
lethal.1,2 The class B PBP3 is a monofunctional peptidoglycan
transpeptidase, which is associated with cell division, where it
cross-links stem peptides of polymerized molecules of lipid II
to create the peptidoglycan mesh essential for bacterial
survival.3,4 β-Lactams inhibit PBPs, initially by competing
with the D-Ala-D-Ala terminus of the stem peptide substrate to
give a non-covalent complex, which then reacts with the active-
site catalytic serine [in Pseudomonas aeruginosa PBP3
(PaPBP3): Ser294] to give an acyl−enzyme complex which
is stable over a biologically relevant timescale.5
The effectiveness of β-lactams to treat Gram-negative
infections caused by Escherichia coli, Klebsiella pneumoniae,
Enterobacter cloacae, Acinetobacter baumannii, and P. aeruginosa
is increasingly compromised by serine- and/or metallo-β-
lactamases (SBLs and MBLs, respectively),6,7 with >1800 BL
variants identified.7 Ambler classes A, C, and D BLs are SBLs,
while those employing a zinc ion-mediated mechanism are
Ambler class B BLs (MBLs).
The ability of penicillins to treat infections is enhanced by
their combination with a class A SBL inhibitor (e.g.,
clavulanate);6,7,9 however, the rise of Class A (i.e., K.
pneumoniae carbapenemases) and class D BLs has compro-
mised this approach. Non-β-lactam-based carbapenemase
inhibitors, that is, diazabicyclooctanes (DBOs), for example,
avibactam, which inhibits class A, C, and some D BLs;6,7,10 and
relebactam, which inhibits class A and C BLs,11−13 show utility
(avibactam and relebactam) and promise (other DBOs) in
restoring the clinical efficacy of β-lactams against some
resistant strains though they are not potent MBL inhibitors.
There is thus a need for new antibiotics to treat a wider
spectrum of resistant Gram-negative infections.14 The develop-
ment of antibiotics with novel modes of action avoiding
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existing resistance mechanisms is time-consuming. An
alternative is to identify new chemo types for validated targets
and to incorporate new features that limit resistance
mechanisms to existing antibiotics.
Following the pioneering clinical development of boronic
acids as protease inhibitors for multiple myeloma treatment,15
interest in boron-containing inhibitors (BCIs) of nucleophilic
enzymes has been growing. The ability of boronates to inhibit
SBLs has long been known. However, it is only recently that
monocyclic (i.e., vaborbactam, which inhibits class A and C
BLs16−18) and bicyclic boronates (e.g., taniborbactam and
structurally related bicyclic boronates, which inhibit members
of all four Ambler classes of BLs including MBLs19−21) suitable
for clinical use/development have been reported. These
compounds bind in a manner that mimics the proposed
“tetrahedral” transition states in SBL and MBL BL catalysis8,22
(Figure 1b). By contrast with the work on SBLs and MBLs,
there are relatively limited reports on the interactions of boron-
based inhibitors with PBPs.22−33 Although there are reports of
boronic acids reacting with PBPs,23,24,26−31,34−36 and with
antibacterial activity,25 there are no reports of potent bicyclic
boron-based PBP inhibitors/antibacterials in the peer-reviewed
literature. The development of dual-action PBP/BL boron-
based inhibitors is also of interest. The bicyclic BCI scaffolds
are of particular interest in part because their rigid nature
compared to acyclic inhibitors may make it easier to develop
selectivity for bacterial PBP and BL targets over nucleophilic
human enzymes. Work with the DBO scaffold, which was
originally developed for SBL inhibition but which was
subsequently developed for antibacterial use,37−39 suggests
that bicyclic boron-based PBP inhibitors might be analogously
developed.
In addition to acting as “transition-state” analogues of BLs,
crystallography reveals the potential for BCIs to undergo
unexpected reactions, for example, formation of a tricyclic
structure with the NDM-1 MBL19 and of a tricovalent binding
mode with D,D-peptidases.27 We are interested in exploring the
reactions of boron-based compounds with PBP inhibitors, with
a view of enabling them as non-β-lactam-based inhibitors that
are not susceptible to BLs.
Here, we report the use of high-throughput protein
crystallography40 to investigate the binding modes of a
fragment library enriched with boron-based compounds to
PaPBP3. The extensive structural results reveal that different
types of potential boron-based inhibitors react differently with
PBPs, in particular boronic acids react to form tricovalent
complexes, while benzoxaboroles form dicovalent complexes.
■ RESULTS
X-ray Fragment Screen. Our previous attempt at high-
throughput (XChem) fragment screening with crystals of
PaPBP3 with a diverse library of >1300 fragments yielded only
a single, covalently reacted hit, a much lower hit rate than
typically expected for such screens.41 We therefore elected to
focus on a covalent fragment library enriched with boron-based
compounds, given their demonstrated reactivity toward serine
nucleophiles.42 In total, 262 compounds (most from Enamine’s
“Serine focused Covalent Fragments” library43), of which 152
were boron-containing compounds, were tested. For compar-
ison, other electrophilic compounds including epoxides and
sulfonyl fluorides and vaborbactam16−18 (a monocyclic
Figure 1. BCIs are proposed to act as mimics of “tetrahedral” transition states arising from enzyme-catalyzed hydrolysis pathways of natural
substrates and β-lactams with PBPs. Outline of general mechanisms of (a) transpeptidase reactions catalyzed by a class B PBP, for example, PaPBP3
and (b) the reaction of β-lactam with PBP3, exemplified with a penicillin. Hydrolysis of the acyl−enzyme complex is typically slow in PBPs but is
rapid in serine-BL (SBL) catalysis. (c) sp3 form of BCIs may mimic the proposed “tetrahedral” transition states and thus bind tightly to the PBP
active site. The ability of boron to “morph” between sp2 and sp3 hybridization states is important in the context of SBL and likely MBL inhibition.8
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boronate SBL inhibitor, which reacts in a monocovalent
manner16) were also included. The library was screened
against PaPBP3 crystals (Figure S4) at both pH 6 and pH 8
because BCIs can interact differently with proteins depending
on the pH.44 Soaking of crystals, harvesting, and data
collection were completed within 24 h. Thirty-four boron-
containing fragments (boronates and benzoxaboroles) and
vaborbactam were determined to be “hits” with various levels
of electron density observed at the active site. The fragments
showed a clear pattern of either tricovalent27 or dicovalent
bonding depending on whether the compound was based on a
boronate or a benzoxaborole scaffold.
Structures of boronates 1 and 2 with PaPBP3 show the
boron atom is sp3-hybridized and tricovalently bonded to
Ser294 (the catalytic serine), Ser349 (from the conserved SxN
motif), and Lys484 (in the KS(T)G motif). The reaction of
Lys484 is notable and may in part reflect a low pKa for this
residue. Previous studies with PBPs have proposed the
presence of a low pKa lysine residue (generally the equivalent
residue to Lys297) in their active sites.29,46−48
The phenyl rings of 1 and 2 occupy similar, but distinct,
regions at the active site. Water occupies the oxyanion hole
that is occupied by the β-lactam-derived carbonyl of PBP
inhibitors (Figure 4 and Figure S5). The tetrazole of 1 makes
hydrogen-bonds to the backbone NHs of Gly534 and Gly535
and is positioned to hydrogen bond with the Thr487 and
Ser485 side chains (Figure 2). The imidazole of 2 also forms a
hydrogen bond with the backbone NH of Gly535 and the
Ser485 side chain. The direct hydrogen-bonds to Gly534 and
Gly535 are unusual for PBP3 inhibitors that occupy the
carboxylic acid binding pocket, that is, the pocket binding the
C-3 penicillin carboxylate (Figure S5). These structures
therefore provide support for the future design of PBP3
inhibitors incorporating either weakly acidic non-carboxylates
or neutral groups49 that interact with the “acid binding pocket”
of PBP3, which is typically occupied by the C-3 carboxylate of
β-lactams (penicillin nomenclature) (Figure S5).
Figure 2. Boronates 1 and 2 react with PaPBP3 in a tricovalent manner. Boronates (a) 1 and (b) 2 react with Ser294, Ser349, and Lys484 (PDB:
7ATM and 7ATO respectively). A dimethyl sulfoxide molecule at the active site in both structures is not shown for clarity (see Figure S10).
Hydrogen bonds are shown as black dashed lines. Unbiased omit Fo-Fc maps are shown (light blue mesh) for the ligand and covalently attached
side chains (contoured at 1σ), as calculated by “comit” in the ccp4 suite.45
Figure 3. Benzoxaboroles react with PaPBP3 in a dicovalent manner. (a) 3 and (b) 4 react covalently with Ser294 and Ser349 and hydrogen bond
with Lys484 (PDB: 7ATW and 7ATX, respectively). Hydrogen bonds are shown as black dashed lines. Unbiased omit Fo-Fc maps (light blue
mesh) are shown for the ligand and covalently attached residue side chains (contoured at 1σ), as calculated by “comit” in the ccp4 suite.45
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Figure 4. Binding mode of PaPBP3 inhibited by piperacillin compared with those for benzoxaboroles 7 and 11. (a) PaPBP3 inhibited by
piperacillin (PDB: 6R3X);51 (b) predicted binding mode of 11 as determined by docking, showing how groups 1 and 2 may engage in the same
manner as analogous groups in piperacillin; (c) binding mode of 7 complexed with PaPBP3 (PDB: 7AU0). Hydrogen bonds are shown as black
dashed lines. An unbiased omit Fo-Fc map is shown (light blue mesh) of the ligand and covalently attached residue side chains (contoured at 1σ),
as calculated by “comit” in the ccp4 suite.45 (d) Structure of piperacillin colored according to its functional groups: β-lactam (orange), C-3
carboxylate (pink), group 1 (blue), and group 2 (green); (e) benzoxaborole 11 was designed to mimic the piperacillin binding mode. Colors match
analogous groups within piperacillin which were hoped would engage the same parts of the protein in the case of 11.
Scheme 1. Synthesis of Benzoxaborole Derivatives (A) 5−10 and 14, (B) 11, and (C) 15a
aReagents and conditions: (a) 1,1′-carbonyldiimidazole, N,N-dimethylformamide (DMF), 40 °C, 4−16 h; (b) LiOH·H2O, 1,4-dioxane/H2O
(3:1), 40 °C, 60 min; (c) HCl (4 M soln. in 1,4-dioxane), CH2Cl2, rt,16 h; (d) Br2, CH2Cl2, rt, 18 h; (e) benzyl bromide, K2CO3, DMF, rt, 4 h; (f)
bis(pinacolato)diboron, Pd(dppf)Cl2, KOAc, dioxane, 80 °C, 12 h; (g) EtOAc, LDA (1 M solution in THF), −78 to −20 °C, 2 h; (h) LiOH·H2O,
THF/H2O (1:1), rt, 2 h. Note that low isolation yields for substituted benzoxaboroles (e.g., 8−10) in part reflect significant losses during
purification on the silica gel and provide scope for further optimization. For B1, R1 = H and R2 = CH(R3)CO2Me. The complete structures of 5−7,
14, and 8−10 are shown in Table 1. Dppf: 1,1′-bis (diphenylphosphino)ferrocene; Boc, tert-butoxycarbonyl; Bn, benzyl.
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A similar tricovalent binding mode is reported for an alkyl
boronate bound to a D,D-peptidase from Actinomadura sp. R39
(PDB: 3ZVT)27 though our work represents the first time
these binding modes have been observed with a HMM PBP.
Notably, the boron atoms of both structures are positioned
similarly within the active site and the side chains of both
nucleophilic serines and lysine align closely, independent of the
nature of the boron-bonded functional group, that is, alkyl
versus phenyl.
The screen also revealed that benzoxaboroles bind to the
PBP active site, but with the boron dicovalently bound to
Ser349 and Ser294 and a hydrogen bond via its “endocyclic”
oxygen to Lys484. Both 3 and 4 form hydrogen bonds to the
side chain NH2 group of Asn351. Like the phenyl boronates, a
water molecule occupies the oxyanion hole and forms
hydrogen bonds to the backbone NH of Ser294 and Thr487.
In the structures for 3 and 4, Tyr409 is hydrogen-bonded to
the backbone carbonyl of Thr487 (Figure 3).
Hit Expansion Design and Synthesis. Due to the
chemically interesting nature of their reaction with the PBP
active site, we investigated the potential of benzoxaboroles for
PBP inhibition. The PaPBP3/3 complex structure, along with
reported structural studies on β-lactams,50,51 was used to
design a set of 6-substituted amides incorporating the features
of the piperacillin C-6 side chain, that is, D-phenylglycine and
diketopiperazine moieties; for synthetic simplicity, a ketopiper-
azine was used to mimic the diketopiperazine. Ideas were
evaluated using docking into the PaPBP3 piperacillin binding
site (Figure 4).
Benzoxaboroles 5-11 with a C-6 acylamino side chain were
synthesized (Scheme 1) and structures of their PaPBP3
complexes solved. As demonstrated by comparison of Figure
4c,e, despite their covalent reaction with Ser294 and Ser349,
5−11 generally failed to engage the active site as proposed and
did not show inhibition (Table 1). Analogues 12, 13 (from
Wuxi AppTec), and 15 (Scheme 1C) with a C-3 carboxylic
acid group were then synthesized. The C-3 carboxylate group
was modeled to align with the analogous C-3 carboxylate
present in penicillins (pink in Figure 4), with the aim of
improving the affinity.
To explore alternatives to amino acid-derived benzoxabor-
oles, 14 and 15 were synthesized (Scheme 1). Once again, a
dicovalent reaction of the boron with both Ser294 and Ser349
was observed. The phenyl groups within the side chains of
both these compounds are situated in a region close to where
the reacted piperacillin phenyl binds (PDB: 6R3X)51 (Figure
S8).
Inhibition Assays. 1−15 were screened for PaPBP3
inhibition at 1 mM using an established fluorescence
anisotropy (FA) assay.52 For selected compounds, inhibition
of hydrolysis of the thioester substrate analogue S2d4,24,53,54
was measured, with good correlation between the results with
the two assays (Table 1). Most compounds manifested
minimal inhibition despite clear evidence of binding in
crystallo. Pre-incubation of 12 with PaPBP3 (0, 30, or 60
min) prior to assay initiation had no significant effect on
inhibition (data not shown). Ki values were determined using
the BOCILLIN FL assay for the four compounds with the
lowest residual activities (12, 13, 15, and vaborbactam), of
which 12 was the most potent with a Ki of 73.9 ± 0.8 μM
(Table 1). 12 was also tested against purified PBP3s from E.
coli, A. baumannii, and Haemophilus influenzae, and PBP2 from
Neisseria gonorrhoeae (equivalent to PBP3)55,56 (Table 2).
Given the sequence (Figure S6) and structural (Figure S7)
similarities of the studied PBP3 variants, the apparent variation
in their activity is interesting, possibly indicating a degree of
selectivity.
To investigate the reversibility of the reaction, we used the
colorimetric substrate nitrocefin, which acylates PaPBP3 and
then rapidly deacylates, with a concurrent color change.22,57,58
Upon twofold dilution of the assay, the half−maximal
inhibitory concentration (IC50) value relative to the unin-
Table 1. Residual Activities and Kis of Compounds Tested
in the BOCILLIN FL Competition Assay for Binding to
PaPBP3 and Residual Activities Measured in S2d Turnover
Assaysa
aFor both BOCILLIN FL FA and S2d assays, residual activities in the
presence of a 1 mM inhibitor are a percentage of the activity of the
untreated control. Errors are standard errors (n = 3) from
independent measurements. bResidual activity measured at 100 μM
due to solubility issues at 1 mM. Ki, calculated with 11 concentrations
of each compound and determined using global fitting in Kintek
Global Explorer.52,59 ND, not determined.
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hibited control was doubled, indicative of rapid (equilibrium
established in <30 s) reversibility. The IC50 of irreversibly
bound ceftazidime was not significantly affected (Figure S3).
Consistent with this is the observation that the progress curves
can be fit well using a simple reversible, one-step binding
model (Figure S2). While the inhibition is weak, these results
are consistent with other investigations of boronate binding in
HMM PBPs, which typically show IC50s in the μM
range.23−25,32,33
Selected compounds were screened against E. coli, P.
aeruginosa, H. influenzae, A. baumannii, and N. gonorrhoeae
and a P. aeruginosa strain engineered to remove the outer
membrane permeability barrier to investigate their antimicro-
bial activity (Table S2).60 All were ineffective (MICs ≥64 μg/
mL). Synergy with piperacillin, a Gram-negative PBP3 specific
β-lactam,61 was not observed in non-BL-expressing E. coli and
P. aeruginosa, although weak synergy was observed in class C
BL-expressing strains (data not shown).
Table 2. Inhibition Properties of Benzoxaborole 12 against
Various PBP variantsa
protein tested residual activity by BOCILLIN FL FA (%)
PBP3 from P. aeruginosa 16 ± 6
PBP3 from H. Influenzae 32 ± 3
PBP3 from A. baumannii 73 ± 3
PBP3 from E. coli >90
PBP2 from N. gonorrhoeae >90
aResidual activities (treatment with 12 (1 mM) for 1 h, the activity
determined by BOCILLIN FL competition assay) are given as a
percentage of the untreated control, with errors as standard deviations
of three technical replicates. Note that the N. gonorrhoeae PBP2 was a
transpeptidase-only construct.
Figure 5. Structures of benzoxaboroles with a C-3 acid group (12, 13, and 15) and 14 complexed with PaPBP3. (a) PaPBP3/12 complex (PDB:
7AU1); (b) PaPBP3/13 complex (PDB: 7AU8); (c) PaPBP3/14 (PDB: 7AU9); and (d) PaPBP3/15 complex (PDB: 7AUB). For clarity, only one
of the two refined conformations of Tyr409 is shown in (a). Hydrogen bonds: dashed black lines. Unbiased omit Fo-Fc maps are shown (light blue
mesh) of the ligand and covalently attached residue side chains (contoured at 1σ), as calculated by “comit” in the CCP4 suite.45
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■ DISCUSSION
The 10 structures of boron compounds reacted with PaPBP3
(Table S2) reveal three distinct binding modes: (i)
monocovalent reaction with Ser294 (Figure 6a), (ii) dicovalent
reaction with Ser294 and Ser349 (Figure 6b), and (iii)
tricovalent reaction with Ser294, Ser349, and Lys484 (Figure
6c). The observed binding mode depends on the nature of the
boron compound, with vaborbactam reacting monocovalently,
benzoxaboroles (3−15) reacting dicovalently, and phenyl
boronates (1 and 2) reacting tricovalently. Tricovalent27 and
monocovalent22,25−27,29,30 bonding of boron compounds with
PBPs are known, but to our knowledge, this is the first time
that benzoxaborole compounds have been shown to bind to a
PBP in a dicovalent manner. Although we cannot rule out the
possibility that some of our structures are a consequence of
crystallization, analogous data were collected at pH 6 and pH
8; the observed covalent binding mode thus does not appear to
correlate with the crystallization conditions but is probably
related to the form of the warhead (Table S3).
Structures of PaPBP3 with 3, 4, 7, 9, 12, 13, 14, and 15
show the benzoxaborole core binding in a conserved manner
(Figure S8). In the dicovalent benzoxaborole binding mode,
the chi1 angle of the Ser294 side chain is the same as in the
monocovalently piperacillin-reacted structure, but the benzox-
aborole and piperacillin-reacted structures have a difference in
the chi2 angle of ∼80° (Figure S9). These observations reveal a
scope for variations in the Ser294 side chain conformation on
covalent inhibitor reaction. By contrast, in all our structures,
Ser349 is not significantly displaced compared to the β-lactam-
reacted structures, for example, piperacillin-reacted PaPBP3
(PDB: 6R3X).51 Similarly, in the tricovalent binding mode of
1, the Ser294 chi1 angle rotates by ∼100°(relative to the
monocovalently reacted structure) (Figure S9), but the Ser349
and Lys484 side chains are not significantly displaced (with Oγ
and Nε being displaced <1 Å relative to their positions in the
piperacillin-reacted structure (PDB: 6R3X)51).
Figure 6. Boron-containing compounds react with a PBP in three distinct modes. The formation of different complexes with exemplary
crystallographically observed complexes are shown. (a) Vaborbactam reacts monocovalently with Ser294; (b) Benzoxaboroles (3−15) bind
dicovalently with Ser294 and Ser349; (c) phenylboronic acids (e.g., 1, 2, and alkyl boronic acids27) bind tricovalently to Ser294, Ser349, and
Lys484. The order of nucleophilic residue reactions is unknown; (d) overlay of crystallographically observed states. The position of the boron can
be described by rotations of the chi angles of the Ser294 side chain. In the monocovalently and dicovalently bound crystal structures [and in the
piperacillin-reacted structure (PDB: 6R3X),51 the chi1 angle of Ser294 is gauche- (∼−60°) relative to the serine amine.64 In contrast, in tricovalent
mode (e.g., 1), the chi1 angle of Ser294 is trans (∼−161°) relative to the amine. There is an 80° difference between the chi2 angles of dicovalent
mode and monocovalent mode (Figure S9).
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It has been suggested that, at least in the context of BL
inhibition, binding to the catalytic serine occurs first, followed
by (where appropriate) reaction with the other nucleophilic
residues.27 In the structures where boron reacts in the
dicovalent manner (see, e.g., Figure 5), substitution of the
strong B−O bond in the five-membered ring of the
benzoxaborole62,63 by the primary amine of Lys484 is likely
unfavorable, explaining why tricovalent binding does not occur.
Our kinetic data indicate that the equilibrium between PBP
and boronate is achieved at least within minutes, supporting a
relatively fast, but weak binding model for boronates to PBPs,
as suggested previously.31 Our method does not allow for
determination of binding rates on the seconds timescale, but
detailed kinetic analysis has been carried out to investigate the
observation of biphasic inhibition curves with some
tricovalently binding BCIs.27 Zervosen et al. concluded that
the biphasic curves were caused by rapid non-covalent
association, followed by slow formation of monocovalent,
tetrahedral complexes.27 The formation of tricovalent com-
plexes was suggested to be in rapid equilibrium with the
monocovalent complex (Figure 6c). Boronates that react with
PBPs monocovalently are proposed to act as analogues of the
tetrahedral transition state (Figure 1);28−30 however, the tri-
and dicovalent binding modes are less obvious transition state
mimics. It remains unclear if the tricovalent binding mode will
be important for developing boron-based PBP inhibitors with
increased potency, or if it is, at least in part, a crystallographic
artifact.
One conclusion from the structural−activity relationships is
that the presence of a C-3 acid group increases potency.
Comparisons of the affinities of 13 (Ki = 172.0 ± 3.0 μM) and
10 (residual activity by BOCILLIN FL FA > 90%)
demonstrate the benefit of a C-3 acid (Table 1). This result
is consistent with the conservation of the C-3 (or equivalent)
carboxylate group across most β-lactam PBP inhibitors and
studies showing addition of a carboxyl group to benzoxabor-
oles leads to a 10−100-fold increase in binding affinity for
some BLs.65
Our structure-based design of boron inhibitors aimed to
utilize analogous hydrogen bond interactions to those made by
reacted piperacillin (Figure 4). However, the constrained
position of the benzoxaborole ring (Figure S8), imposed by the
dicovalent bond formation and rigid 6−5 ring system, meant
key hydrogen bond interactions, particularly those to the
backbone of the β3 strand (Thr487 and Arg489), could not be
made by the C-6 amide group (blue in Figure 4d), likely
contributing to the lack of inhibition shown for some
compounds (5−10). The position of the C-6 amide group
did enable hydrogen bonding with the highly conserved
Asn351, a hydrogen bond observed in many β-lactam-reacted
PBP complexes (Figure 4a).
Exploration of C-5-substituted benzoxaboroles employing
structural insights revealed here could lead to further potency
improvements. Thus, for example, while 14 did not inhibit
PaPBP3, similar to the other benzoxaboroles without an acid
group, one of its benzyl groups is positioned near the D-Phe
position of reacted piperacillin and the other is positioned
close to key active-site residues. The structure with 15 (Ki =
78.1 ± 0.9 μM) places the phenyl of the C-5 benzylether
benzoxaborole substituent in the same PaPBP3 active-site
location as the phenyl rings in piperacillin- and amoxicillin-
derived adducts.
Importantly, structures of 1 and 2 demonstrate the potential
for non-acid groups to engage the PBP3 acid binding pocket
optimized binding of these groups may be used to combat
point mutation-mediated resistance in this region.51
Examination of the reported PaPBP3 structures50,51,66−69
reveals the β5-α11 loop (residues 528−539, Figure S10)
adopts different conformations. The β-lactam-containing
PaPBP3 inhibitors (e.g., amoxicillin, aztreonam, ceftazidime,
and piperacillin50,51) induce formation of a “hydrophobic wall”
composed of Tyr533, Phe532, and residues within the β5-α11
loop together with Tyr503.50 Meropenem, which lacks a
hydrophobic C-6 group, by contrast, does not induce the
formation of this “hydrophobic wall” (PDB: 3PBR),50 while
apo PaPBP3 adopts a third conformation for the β5-α11 loop
(Figure S10, PDB: 6HZR).51
In most of our PaPBP3 boron-based compound structures
(e.g., 12), the electron density maps in the region of the β5-
α11 loop were of insufficient quality to enable residues to be
fitted. However, although the observed densities were weak
(Figure S10), in the complexes with 1, 3, and 13, unique
conformations of the β5-α11 loop were observed. Benzox-
aboroles 9, 11, 12, 14, and 15 were designed to have a phenyl
group, binding of which may mimic that of the D-Phe of
reacted piperacillin in interactions with the hydrophobic wall
(Figure S11). While the phenyl group of 14 and 15 is
positioned close to the position of the D-Phe of reacted
piperacillin, the hydrophobic wall was not formed on binding,
perhaps in part reflecting the poor potency of these
compounds.
Figure 7. Binding of 2 causes changes in the PaPBP3 active-site conformation. Views of benzoxaborole PaPBP3/2 (orange, PDB: 7ATO) and
piperacillin-reacted PaPBP3 (black, PDB: 6R3X)51 (protein backbone colored blue and gray, respectively) are shown. A clear unprecedented
difference in the α10-β3 loop conformation (residues 466−473) is observed. See also Figure S14.
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The conformation of the β3 β-strand is associated with
hydrophobic wall formation possibly mediated by inhibitor
interactions with Thr487 and Arg489 .50 The overall fold of
PaPBP3 bound to 12, which lacks the ketopiperazine terminal
substituent, is similar to that in the meropenem-reacted
PaPBP3 complex (Figure S12, PDB: 3PBR).50 In both these
structures, Tyr409 forms a hydrogen-bond to the backbone
carbonyl of Thr487, whereas with amoxicillin, aztreonam,
ceftazidime, and piperacillin, the inhibitor-derived adducts
form a direct hydrogen-bond to the backbone carbonyl of
Thr487 (Figure S12). The rigid dicovalent binding mode of
the benzoxaborole core (Figure S8) prevents the C-6 amide
from directly forming hydrogen-bonds to the backbone
carbonyl of Thr48. A structure of PaPBP3 complexed with
13, which has a ketopiperazine substituent but which lacks a
phenyl analogous to that of the D-Phe of piperacillin, has β5-
α11 loop and β3 β-strand conformations similar to those
observed in the piperacillin-reacted PaPBP3 (Figure S13).
Interestingly, both the ketopiperazine of 13 and the
diketopiperazine of reacted piperacillin form hydrogen bonds
with the Oη oxygens of Tyr328 and Tyr407 (Figure S13).
Further optimization of the side chains of the benzoxaboroles
may be able to better exploit the interactions possible with the
β3 strand backbone, Tyr328 and Tyr407, and the hydrophobic
wall regions, leading to improved binding.
Variations in the α10-β3 loop were observed in the PaPBP3/
2 complex (Figures 7 and S14), that is, it adopts a
conformation not previously observed in PaPBP3 structures.
The largest displacements, relative to the piperacillin-reacted
structure, are for residues Gly469, Gly470, and Val471 (7.2,
10.2, and 9.9 Å, respectively). The significance of these
movements is unclear. The structure of PaPBP3/12 was
refined with two conformations for Val476-Pro-Gly-Tyr-His480
of the α10-β3 loop (Figure S15). These structures appear to
nicely exemplify how, when combined with high-throughput
crystallography, the ability of boron-based compounds to
interchange between different forms (including sp2 and sp3
forms) during their reactions with proteins can be employed to
reveal otherwise latent conformations.
Vaborbactam, an approved monocyclic SBL inhibitor17
without reported antimicrobial activity, was included in our
studies to investigate its potential interactions with PaPBP3
compared to the other BCIs. Our PaPBP3/vaborbactam
structure shows a monocovalent reaction, as observed with
SBLs16 (Figure 8). The structures of vaborbactam and
amoxicillin in complex with PaPBP3 superimpose well,
including with respect to the oxyanion hole, the C-3
carboxylate, their amide bonds, and in the position of their
aromatic rings (Figure S16). Similar to amoxicillin, vaborbac-
tam is positioned to form hydrogen bonds with residues
including with Asn351, Tyr409, Thr487, and Ser485 as well as
well to engage with the hydrophobic wall (residues Tyr503,
Tyr532, and Phe533). Despite these favorable interactions,
vaborbactam binds poorly to PaPBP3 in solution (Table 1),
consistent with its lack of antimicrobial activity.
■ CONCLUSIONS
The multiple PBP3 structures reported here with three
different classes of boron-based compounds, that is, boronic
acids, and predominantly mono- (vaborbactam) and bicyclic
(benzoxaboroles) boronates, reveal three distinct binding
modes. Vaborbactam forms a covalent bond reacting with
the catalytic serine, whereas the benzoxaboroles form
dicovalent complexes (additionally reacting with Ser349),
and the boronic acids form tricovalent complexes (additionally
reacting with Lys484). While these binding modes are
precedented with other nucleophilic serine enzymes,27,70,71
the generality of the reactions is notable, in particular for the
tricovalent reactions observed for the boronic acids. Given the
binding modes as reflected by crystallography (though not as
yet validated in solution) and that SBL/MBL inhibition by
boron-containing compounds has been demonstrated, it is
perhaps surprising that the compounds described here are not
more potent PaPBP3 inhibitors though affinities for boronates
against essential PBPs have typically been poor.22−25 Recent
patent reports concerning compounds with a bicyclic boronate
(taniborbactam-like) scaffold show promising activity against
PBPs,32,33 but a clear explanation for the differential potencies
of boronate inhibition of BLs versus PBPs has yet to be
established.8 Our combined results imply that the rigid nature
of the di- and tricovalent complexes formed may require rather
precise derivatization of the boron scaffold to obtain potent
inhibition. Consistent with this, our attempt to combine the
benzoxaborole PBP3 structures with those of β-lactams (e.g.,
piperacillin) did not give potent inhibitors. An interesting
observation from the crystallography was of the influence of
the boron inhibitors on the conformation of the β5-α11 and
α10-β3 loops. The results presented here and elsewhere
suggest that conformational changes during active-site ligand
binding are important for inhibition and (likely) also induced
fit substrate binding. The “morphing” ability of boron-
containing ligands, combined with high-throughput crystallog-
raphy to reveal otherwise latent structural changes, is notable.
However, it is presently difficult to predict how specific active-
site interactions may influence conformational changes for the
active site. Indeed, the results suggest that the lack of potency
of the PBP inhibition of compounds described here and
elsewhere may relate to non-optimal interactions with mobile
regions in and around the PBP active site. Thus, from a
medicinal chemistry perspective, it may be most efficient to
employ a combination of structure-guided (core scaffold) and
empirical (side chain) approaches.
Insights from our PaPBP3/benzoxaborole structures com-
bined with reported structures for piperacillin-, aztreonam- and
ceftazidime-reacted complexes provide a strong knowledge
base that will enable further explorations of benzoxaboroles as
non-β-lactam-based PBP inhibitors. The PaPBP3 structures
Figure 8. Binding of vaborbactam to PaPBP3. Hydrogen bonds: black
dashed lines. An unbiased omit Fo-Fc map is shown (light blue mesh)
of the ligand and covalently attached residue side chains (contoured
at 1 σ), as calculated by “comit” in the ccp4 suite.45 PDB code 6AUH.
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with 14 and 15 are interesting as they indicate vectors to target
key PBP active-site interaction hotspots for improving affinity.
If benzoxaborole PaPBP3 potency can be improved, there is
patent literature precedent that boron-based PBP inhibitors
can achieve MICs of 8−16 μg/mL in CTX-M-15-expressing E.
coli strains.32,33 Given the pressing need for novel antibiotics
against resistant Gram-negative bacteria, further exploration of
benzoxaboroles and related PBP inhibitors is a promising
approach to new antibiotics targeting PBPs.
■ EXPERIMENTAL SECTION
Protein Synthesis and Crystallography. Genes encoding for
recombinant PBP3s from P. aeruginosa, E.coli, A. baumannii, and H.
influenzae were expressed as soluble fragments to produce proteins
with PBP residues 50−579, 60−588, 64−609, and 80−610,
respectively, which lack the N-terminal transmembrane helix anchor.
A soluble construct expressing only the C-terminal transpeptidation
domain of N. gonorrhoeae PBP2 (residues 237−581) (a class B PBP
with close analogy to the PaPBP3 protein, with different
nomenclatures for historical reasons)55,56 from the clinical muta-
tion-mediated penicillin-resistant N. gonorrhoeae (FA6140) was used.
All proteins were produced and purified as described using reverse
nickel affinity chromatography utilizing the HRV 3C protease to
cleave the N-terminal His6 expression tags.51
PaPBP3 crystals were obtained at 294 K using the hanging drop
vapor diffusion method by mixing equal volumes of 10 mg/mL
protein with the following precipitant solutions: 25% (w/v)
polyethylene glycol 3 350, 1% (w/v) protamine sulfate, and 0.1 M
Bis-Tris propane at pH 6 or 8.66 Crystals were cryoprotected with
20% (v/v) glycerol prior to flash-freezing in liquid nitrogen.
Inhibitor−protein complexes were obtained by soaking crystals
overnight with a 250 mM solution of the requisite compound.
Diffraction data were collected on Diamond beamlines I03, I04, and
I04-1. All data were processed using autoPROC and STARANISO72
due to significant anisotropy of the data, with the exception of the
complexes of PaPBP3 with 7 and 15, which were isotropic and which
were processed with autoPROC.73 Structures were phased by
Phaser_MR74 using a high-resolution structure of PaPBP3 (PDB:
6HZR).51 Manual building and ligand fitting were performed with
COOT.75 Refinement was carried out primarily using REFMAC576
within the CCP4 suite45 as well as in phenix.refine.77 Structures were
validated with MolProbity.78 Figures of structures were prepared
using PyMOL (The PyMOL Molecular Graphics System, Schrö-
dinger, LLC) or CCP4mg.79
BOCILLIN FL Assays. Unless otherwise stated, assays were run in
triplicate using a 60 nM purified protein (see above), 30 nM
BOCILLIN FL in pH 7 100 mM sodium phosphate buffer, with
0.01% Triton to reduce promiscuous ligand binding23 and reduce
binding of the protein to the plate. Assays were run in triplicate in a
volume of 50 μL, in black, flat-bottom, 384-well microplates (Grenier
Bio-One, Austria) at 30 °C. The change in FA was measured using a
ClarioStar plate reader (BMG Labtech) with polarized filters at
excitation: 482−16, emission: F: 530−4, and calculated using MARS
software v3.32 (BMG Labtech) using the equation
F F F Ffluorescence anisotropy ( )/( 2 )para perp para perp= − +
where Fpara is the fluorescence intensity parallel to the excitation plane
and Fperp is fluorescence intensity perpendicular to the excitation
plane.
Residual activities were determined by pre-incubating the test
compound (1024 μM) and protein for 1 h at 30 °C before the
reaction was initiated by the addition of BOCILLIN FL. The change
in FA after 30 min was compared to the uninhibited control to
determine the residual activity. In order to calculate Ki, the compound
(at 11 concentrations: 1−1024 μM) and BOCILLIN FL were mixed
and the reaction was initiated by the addition of PBP. Also included in
the model were progress curves of nine concentrations of PBP (40−
110 nM). Inhibition plots with meropenem and ceftazidime were
done to ensure the correct parameters for BOCILLIN FL binding
were used. Progress curves were analyzed with KinTek, USA, as
described;52,69 reported errors represent the standard error. The
acylation of a PBP by BOCILLIN FL (Figure S1) can be described by
a simple one-step model.52 However, unlike the previous studies, we
found it was necessary to include a term (k2) to account for the
deacylation of BOCILLIN FL to release a hydrolyzed product (Figure
S1). The fluorescence intensity was constant throughout the reaction.
Inhibitor binding was modeled as a reversible reaction to form the
enzyme−inhibitor complex (Figure S1). Ki was calculated as the ratio
of the off-rate koff to the on-rate kon (Figure S1). Inhibitor binding
fittings are shown in Figure S2.
S2d Assays. Residual activities were measured by the ability of a
potential inhibitor to hinder hydrolysis of the substrate analogue S2d
(2-((benzoyl-D-alanyl)thio)acetic acid) turnover by PaPBP3 as
described for other PBPs.4,24,53,54 Assays were conducted in 50 μL
in a 384-well, clear-bottom, black-walled microplate (Greiner Bio-
One). PaPBP3 (400 nM) was incubated with 2 mM of each
compound for 1 h at 30 °C in 100 mM sodium phosphate, pH 7,
supplemented with 0.01% (v/v) triton. A solution of 5,5′-dithiobis-(2-
nitrobenzoic acid) and S2d diluted in the same buffer (to give a final
concentration in the assay of 1 mM for both reagents) was added to
each well to initiate the reaction. The final concentration of protein
was 200 nM and the final inhibitor concentration was 1 mM. A
ClarioStar plate reader (BMG Labtech) was used to follow the
reaction by observing the change in absorbance at 412 nm at 30 °C.
The same assay was conducted in the absence of the inhibitor and
additionally with an excess of aztreonam (1 mM), which completely
inhibits PaPBP3; the results of this were used as a control to
determine the rate of spontaneous S2d hydrolysis in the absence of an
enzyme. The initial rate of S2d turnover was calculated using
GraphPad prism (Prism 8 for macOS, GraphPad Software LLC) and
the standard error calculated from three independent technical
replicates. The rate of non-enzymatic S2d hydrolysis was subtracted
from each rate to find the corrected rate. For each compound, the
ratio of the corrected rate to the untreated control corrected rate was
expressed as a percentage to give the residual activity.
residual activity(%) 100
initial rate in the presence of inhibitor non enzymatic rate
initial rate of untreated control non enzymatic rate
=
×
[ ] − [ ‐ ]
[ ] − [ ‐ ]
Methods for conducting the nitrocefin assay and microbiology are
provided in the Supporting Information.
Interference Considerations. The activity of all the compounds
(1−15) belonging to the same class were analyzed by two orthogonal
methods (FA and absorbance) with good correlation between the
results of both assays. Triton (0.01% v/v) was added to the buffer for
both assays, which should reduce interference by aggregators.
Moreover, a nitrocefin dilution assay indicates that the interaction
of 12 with PaPBP3 is reversible and well behaved (Figure S3). The
weak interaction of 12 with closely related PBPs from other bacteria
indicates that the reaction is selective (Table 2). Lastly, for boronic
acids (PaPBP3/1 and PaPBP3/2, Figure 2) and benzoxaboroles
(PaPBP3 in complex with 3, 4, 7, 12, 13, 14, and 15, Figure S8),
multiple crystal structures demonstrate a conserved binding mode,
specifically engaging active-site residues. The interaction is consistent
with examples from the literature of nucleophilic residue engagement
by boron-based compounds (Figure S17).
1−15 were also screened in silico (http://zinc15.docking.org/
patterns/home) for predicted PAINS and aggregator functional
groups, but none were identified. During the design of the compounds
(1−15), we aimed to obtain polar compounds to limit the chance of
aggregation and avoided functional groups which can cause redox
activity, fluorescence, protein reactivity, singlet-oxygen quenching,
and so forth. The purity of each compound was >95%, minimizing the
presence of impurities.
Synthetic Chemistry. All reagents were from Sigma-Aldrich,
Fisher Scientific, Combi-Blocks, Enamine, or Fluorochem and were
used without further purification. 1 ((3-(1H-tetrazol-5-yl)phenyl)-
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boronic acid) and 3 (1-hydroxy-1,3-dihydrobenzo[c][1,2]oxa-borole-
6-carboxylic acid) were from Combi-Blocks, Inc. 2 ((5-methyl-1H-
indazol-6-yl)boronic acid)) and 4 (4-(1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborole-6-carbonyl)-1,3,3-trimethylpiperazin-2-one) were
from Enamine. These were used without further purification in the
X-ray fragment screen. 3 was purchased from Combi-Blocks, Inc.; 12
and 13 were purchased from Wuxi Apptec; vaborbactam was
purchased from MedChemExpress. 2-((Benzoyl-D-alanyl)thio)acetic
acid (S2d) was synthesized as reported; the spectroscopic data were
consistent with the ones previously reported.80
Solvents were used as received. Flash column chromatography was
performed using a Teledyne ISCO flash purification system using a
Silicycle SiliaSep C18 cartridge. Purity of all final derivatives for
biological testing was confirmed to be >95% as determined using an
Agilent ultra-performance liquid chromatograph−mass spectrometer
(Agilent Technologies 6150 quadrupole, ES ionization) coupled with
an Agilent Technologies 1290 Infinity II series UPLC system Agilent
1290 series high-performance LC (HPLC) at two wavelengths of 254
and 280 nm using the following conditions: Kinetex 1.7 μm Evo C18
100A, LC column 50 × 2.1 mm, solvent A of 0.1% (v/v) (formic
acid) water, and solvent B of 0.1% (v/v) (formic acid) in acetonitrile.
1H and 13C nuclear magnetic resonance (NMR) spectra were
recorded using a Varian Mercury 300 MHz spectrometer or a Bruker
AVIII 600 MHz instrument. Deuterated solvents were used as
supplied. Chemical shifts (δ), referenced using residual solvent peaks,
are reported in parts per million downfield from residual solvent peak
as an internal standard. Multiplicity is given as s (singlet), d (doublet),
t (triplet), q (quartet), m (multiplet), br (broad), or a combination of
these. Coupling constants, J, are reported in hertz (Hz) to the nearest
0.5 Hz. High-resolution mass spectra were recorded using a Bruker
MicroTOF instrument with an electrospray ionization source and
time of flight (TOF) analyzer. The parent ion is quoted with the
indicated ion: [M − H]− or [M + Na]+.
General Protocol 1: Amide Coupling. To a solution of the
appropriate carboxylic acid (1 equiv) in N,N-DMF (2 mL) was added
1,1′-carbonyldiimidazole (CDI) (2 equiv). The reaction was stirred
for 5 min at room temperature; the appropriate amine (1, 1.2, or 1.5
equiv) was then added, and the reaction was stirred for 4−16 h at 40
°C. The solvent was removed in vacuo, and the crude product was
purified using a Teledyne ISCO CombiFlash chromatography system
eluting with a reverse phase solvent gradient of MeOH in 0.1% (v/v)
CH3CO2H/water and a C18 column. The product-containing
fractions were then combined, and the organic solvent was removed
in vacuo. When amide coupling yielded a target intermediate
compound (e.g., methyl esters of general structure B1, Scheme 1),
it was used in the next step without further purification, else
lyophilization was used to afford the desired products as solids (i.e.,
for 5−10 and 14).
1-Hydroxy-N-[2-(methylamino)-2-oxo-ethyl]-3H-2,1-ben-
zoxaborole-6-carboxamide (5). General Protocol 1 was followed
using the following quantities of reagents: 3 (100 mg, 0.56 mmol, 1
equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole (182 mg, 1.12
mmol, 2 equiv); 2-amino-N-methylacetamide HCl (104 mg, 0.84
mmol, 1.5 equiv). Product: crystalline solid (47 mg, 32%). Purity:
>96% (by HPLC). 1H NMR (600 MHz, DMSO-d6): δ 9.55 (br s, 1H,
OH), 8.71 (t, J = 6.0 Hz, 1H, NH), 8.18 (s, 1H, Ar−H), 7.93 (dd, J =
8.0, 2.0 Hz, 1H, Ar−H), 7.85 (q, J = 5.0 Hz, 1H, NHCH3), 7.49 (d, J
= 8.0 Hz, 1H, Ar−H), 5.02 (s, 2H, −CH2OB), 3.85 (CH2, obscured
by the solvent peak), 2.59 (d, J = 5.0 Hz, 3H, CH3);
13C NMR (151
MHz, DMSO-d6): δ 170.3, 167.8, 157.6, 133.2, 130.3, 130.1, 121.9,
70.4,43.1, 26.1; LCMS (ESI+, m/z), 249 [M + H]+; HRMS (ESI−
TOF) calcd for C11H13N2O4
10B; [M − H]−, 247.0896; found,
247.0895.
N-[(1R)-2-Amino-1-benzyl-2-oxo-ethyl]-1-hydroxy-3H-2,1-
benzoxaborole-6-carboxamide (6). General Protocol 1 was
followed using the following quantities of reagents: 3 (100 mg, 0.56
mmol, 1 equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole (182
mg, 1.12 mmol, 2 equiv); (R)-2-amino-3-phenylpropanamide HCl
(169 mg, 0.84 mmol, 1.5 equiv). Product: crystalline solid (80 mg,
43%). Purity: >98% (by HPLC). 1H NMR (600 MHz, DMSO-d6): δ
9.31 (br s, 1H, OH), 8.45 (d, J = 8.5 Hz, 1H, NH), 8.18−8.15 (m,
1H, Ar−H), 7.89 (dd, J = 8.0, 2.0 Hz, 1H, Ar−H), 7.59−7.52 (m, 1H,
Ar−H), 7.46 (d, J = 8.0 Hz, 1H, Ar−H), 7.33−7.30 (m, 2H, NH2),
7.24 (t, J = 7.5 Hz, 2H, Ar−H), 7.20−7.13 (m, 1H, Ar−H), 7.12−
7.08 (m, 1H, Ar−H), 5.02 (s, 2H, −CH2OB), 4.66 (ddd, J = 10.5, 8.5,
4.0 Hz, 1H, −CHNH), 3.12 (dd, J = 14.0, 4.0 Hz, 1H, −CH2Ph), 2.99
(dd, J = 14.0, 4.0 Hz, 1H, −CH2Ph); 13C NMR (151 MHz, DMSO-
d6): δ 173.8, 166.9, 157.3, 139.0, 133.5, 130.3, 130.2, 129.6, 128.5,
126.7, 121.6, 70.4, 55.2, 37.7; LCMS (ESI+, m/z), 325 [M + H]+;
HRMS (ESI−TOF) calculated for C17H17N2O410B [M + Na]+,
347.1174; found, 347.1176.
Methyl (2R)-2-[(1-hydroxy-3H-2,1-benzoxaborole-6-
carbonyl)amino]-2-phenyl-Acetate (7). General Protocol 1 was
followed using the following quantities of reagents: 3 (100 mg, 0.56
mmol, 1 equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole (182
mg, 1.12 mmol, 2 equiv); methyl (2R)-2-amino-2-phenyl-acetate (139
mg, 0.84 mmol, 1.5 equiv). Product: crystalline solid (38 mg, 20%).
Purity: >96% (by HPLC). 1H NMR (600 MHz, DMSO-d6): δ 9.32
(br s, 1H, OH), 9.20 (d, J = 7.0 Hz, 1H, NH), 8.26 (t, J = 1.0 Hz, 1H,
Ar−H), 7.99 (dd, J = 8.0, 2.0 Hz, 1H, Ar−H), 7.52−7.45 (m, 3H,
Ar−H), 7.43−7.31 (m, 3H, Ar−H), 5.68 (d, J = 7.0 Hz, 1H,
−NHCH), 5.04 (s, 2H, −CH2OB), 3.66 (s, 3H, −OCH3); 13C NMR
(151 MHz, DMSO-d6): δ 171.6, 167.4, 157.7, 137.6, 136.7, 133.0,
130.7, 129.3, 128.7, 127.6, 70.4, 57.4, 52.8; LCMS (ESI+, m/z), 326
[M + H]+; HRMS (ESI−TOF) calculated for C17H16N1O510B [M +
Na]+, 348.1014; found, 348.1016.
N,N-Dibenzyl-1-hydroxy-3H-2,1-benzoxaborole-6-carboxa-
mide (14). General Protocol 1 was followed using the following
quantities of reagents: 3 (100 mg, 0.56 mmol, 1 equiv); N,N-DMF (2
mL); 1,1-carbonyldiimidazole (182 mg, 1.12 mmol, 2 equiv);
dibenzylamine (133 mg, 0.67 mmol, 1.2 equiv). Product: crystalline
solid (20 mg, 10%). Purity: >99% (by HPLC).1H NMR (300 MHz,
DMSO-d6): δ 9.26 (br s, 1H, OH), 7.85 (s, 1H, Ar−H), 7.61−7.52
(m, 1H, Ar−H), 7.47 (d, J = 8.0 Hz, 1H, Ar−H), 7.44−7.08 (m, 10H,
Ar−H), 5.02 (s, 2H, −CH2OB), 4.75−4.24 (m, 4H, 2× −CH2Ph).
13C NMR (151 MHz, DMSO-d6): δ 171.6, 167.4, 157.7, 136.7, 133.0,
130.7, 130.6, 129.3, 129.0, 128.7, 121.7, 70.4, 57.4, 52.7; LCMS
(ESI+, m/z), 358 [M + H]+; HRMS (ESI−TOF) calcd for
C22H20N1O3
10B [M + Na]+, 380.1429; found, 380.1429.
General Protocol 2: Synthesis of 8, 9, and 10 (Scheme 1A).
Step (i): General Protocol 1 was followed to afford an appropriate
methyl ester intermediate, B1, which was then directly subjected to
saponification. Step (ii): To a solution of B1 (1 equiv) in 1,4-
dioxane/water (3:1; 10 mL) was added lithium hydroxide
monohydrate (either 4 or 6 equiv.) in one portion. The reaction
mixture was then stirred for 1 h at 40 °C before the volatiles were
removed in vacuo. The residue thus obtained was then lyophilized to
afford corresponding free carboxylic acids (confirmed by LC−MS
analysis) as solids. Step (iii): Crude carboxylic acids were immediately
coupled with selected piperazin-2-one derivatives using conditions
outlined in General Protocol 1, giving target benzoxaboroles as solids.
1-Hydroxy-N-[2-oxo-2-(3-oxopiperazin-1-yl)ethyl]-3H-2,1-
benzoxaborole-6-carboxamide (8). General Protocol 2 was
followed with the following quantities of reagents: step (i): 3 (250
mg, 1.40 mmol, 1 equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole
(455 mg, 2.8 mmol, 2 equiv.) methyl glycinate HCl (133 mg, 0.67
mmol, 1.2 equiv). Step (ii): methyl 2-[(1-hydroxy-3H-2,1-benzox-
aborole-6-carbonyl)amino]acetate (349 mg, 1.40 mmol, 1 equiv); 1,4-
dioxane/water (3:1; 10 mL); lithium hydroxide monohydrate (235
mg, 5.61 mmol, 4 equiv). Step (iii): 2-[(1-hydroxy-3H-2,1-
benzoxaborole-6-carbonyl)amino]acetic acid (50 mg, 0.21 mmol, 1
equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole (69 mg, 0.69
mmol, 2 equiv); piperazin-2-one (32 mg, 0.32 mmol, 1.5 equiv).
Product: crystalline solid [14 mg, 4% (over three steps)]. Purity:
>97% (by HPLC). 1H NMR (600 MHz, DMSO-d6): δ 9.37 (br s, 1H,
OH), 8.63−8.56 (m, 1H, NH), 8.33−8.20 (m, 1H, Ar−H), 7.96 (dd,
J = 8.0, 2.0 Hz, 1H, Ar−H), 7.51 (d, J = 8.0 Hz, 1H, Ar−H), 5.05 (s,
2H, −CH2OB), 4.21−4.10 (m, 3H, CH2), 3.96 (s, 1H, CH2), 3.72−
3.61 (m, 2H, CH2), 3.32−3.18 (m, 2H, CH2); 13C NMR (151 MHz,
DMSO-d6): δ 172.1, 155.5, 135.4, 129.2, 129.2, 129.2, 129.1, 129.1,
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127.9, 127.6, 127.5, 122.1, 70.4, 52.1; LCMS (ESI+, m/z), 318 [M +




carboxamide (9). General Protocol 2 was followed using the
following quantities of reagents: Step (i): 3 (100 mg, 0.56 mmol, 1
equiv); DMF (2 mL); 1,1-carbonyldiimidazole (182 mg, 1.12 mmol,
2 equiv); methyl D-phenylalaninate hydrochloride (121 mg, 0.56
mmol, 1 equiv). Step (ii): methyl(1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborole-6-carbonyl)-D-phenylalanine (187 mg, 0.55 mmol, 1
equiv); 1,4-dioxane/water (3:1; 10 mL); lithium hydroxide
monohydrate (139 mg, 3.31 mmol, 6 equiv). Step (iii): (1-hydroxy-
1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-D-phenylalanine (30
mg, 0.09 mmol, 1 equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole
(30 mg, 0.18 mmol, 2 equiv); 1-methylpiperazin-2-one (16 mg, 0.14
mmol, 1.5 equiv). Product: crystalline solid [16 mg, 8% (over 3
steps)]. Purity: >97% (by HPLC). 1H NMR (300 MHz, DMSO-d6):
δ 8.85 (br s, 1H, OH), 8.24−8.16 (m, 1H, NH), 7.98−7.86 (m, 1H,
Ar−H), 7.48 (d, J = 8.0 Hz, 1H, Ar−H), 7.36−7.14 (m, 6H, Ar−H),
5.20−4.95 (m, 2H, −CH2OB), 4.20−3.93 (m, 2H), 3.34−2.96 (m,
5H), 2.80 (s, 3H); LCMS (ESI+, m/z), 422 [M + H]+.
1-Hydroxy-N-[2-(4-methyl-3-oxo-piperazin-1-yl)-2-oxo-
ethyl]-3H-2,1-benzoxaborole-6-carboxamide (10). General Pro-
tocol 2 was followed with the following quantities of reagents: Step
(i): 3 (250 mg, 1.40 mmol, 1 equiv); N,N-DMF (2 mL); 1,1-
carbonyldiimidazole (455 mg, 2.8 mmol, 2 equiv.) methyl glycinate
HCl (133 mg, 0.67 mmol, 1.2 equiv). Step (ii): methyl 2-[(1-hydroxy-
3H-2,1-benzoxaborole-6-carbonyl)amino]acetate (349 mg, 1.40
mmol, 1 equiv); 1,4-dioxane/water (3:1; 10 mL); lithium hydroxide
monohydrate (235 mg, 5.61 mmol, 4 equiv). Step (iii): 2-[(1-
hydroxy-3H-2,1-benzoxaborole-6-carbonyl)amino]acetic acid (47 mg,
0.2 mmol, 1 equiv); N,N-DMF (2 mL); 1,1-carbonyldiimidazole (65
mg, 0.4 mmol, 2 equiv); 1-methylpiperazin-2-one (34 mg, 0.30 mmol,
1.5 equiv). Product: crystalline solid [17 mg, 5% (over 3 steps)].
Purity: >96% (by HPLC).1H NMR (300 MHz, DMSO-d6): δ 8.58
(br s, 1H, OH), 8.26 (s, 1H, Ar−H), 7.97 (d, J = 6.0 Hz, 1H, Ar−H),
7.51 (d, J = 8.0 Hz, 1H, Ar−H), 5.05 (s, 2H, CH2), 4.24−4.07 (m,
3H, −CH2OB and CH2), 4.05−3.94 (m, 2H, CH2), 3.48−3.30 (m,
2H, CH2), 2.89 (s, 3H, −NCH3); 13C NMR (151 MHz, DMSO-d6):
δ167.6, 167.3, 165.2, 157.5, 133.4, 130.2, 130.0, 121.8, 70.3, 48.0,
47.5, 46.2, 41.2, 33.9; LCMS (ESI+, m/z), 332 [M + H]+.
Synthesis of 11 (Scheme 1B). Step (i). To a solution of (11a)
(tert-butoxycarbonyl)-D-phenylalanine) (300 mg, 1.13 mmol) in N,N-
DMF (3 mL) was added 1,1-carbonyldiimidazole (367 mg, 2.26
mmol); the reaction was stirred for 5 min at room temperature. To
the reaction mixture was then added piperazin-2-one (170 mg, 1.70
mmol) and the resultant solution was stirred for 4 h at 40 °C. Ethyl
acetate (10 mL) and water (10 mL) were added. The layers were
separated. The aqueous layer was extracted with ethyl acetate (3 × 20
mL). Combined organic layers were dried (MgSO4), filtered, and
concentrated in vacuo to afford 11b (tert-butyl N-[(1R)-1-benzyl-2-
oxo-2-(3-oxopiperazin-1-yl)ethyl]carbamate) as a yellow oil (350 mg,
88%), which was used in the next step without further purification.
Step (ii). To a stirred solution of (11b) (350 mg, 1.01 mmol, 1
equiv) in CH2Cl2 (10 mL) was added HCl (4 M in 1,4-dioxane, 0.76
mL, 3.02 mmol, 3 equiv) at room temperature under nitrogen. The
reaction mixture was stirred overnight to afford an insoluble
precipitate. The precipitate, 11c, was washed three times with
CH2Cl2 and then filtered, dried in air, and used in the next step
without further purification (54 mg, 19%).
Step (iii). General Protocol 1 was followed using the following
quantities of reagents: 3 (54 mg, 0.3 mmol, 1 equiv); N,N-DMF (3
mL); 1,1-carbonyldiimidazole (98 mg, 0.600 mmol, 2 equiv); 11c
(103 mg, 0.360 mmol, 1.2 equiv). Product (11): white powder (20
mg, 16%). Purity: >99% (by HPLC). 1H NMR (300 MHz, methanol-
d4): δ 8.31 (br s, 1H, OH), 8.14 (dd, J = 8.0, 2.0 Hz, 2H, Ar−H), 7.93
(d, J = 8.0 Hz, 1H, Ar−H), 7.56−7.45 (m, 2H, Ar−H), 7.36−7.22 (m,
3H, Ar−H), 5.15 (m, 5H, 2× CH2 and CH), 4.33−3.96 (m, 2H,
CH2), 3.88−3.40 (m, 3H, CH2), 3.28−3.06 (m, 3H, CH2); 13C NMR
(151 MHz, DMSO-d6): δ 170.5, 167.3, 167.3, 157.8, 137.7, 132.1,
131.9, 130.3, 129.6, 128.7, 127.1, 122.5, 70.4, 51.5, 46.1, 42.3, 40.4,
37.5; LCMS (ESI+, m/z), 408 [M + H]+; HRMS (ESI−TOF) calcd
for C21H22N3O5
10B [M + Na]+, 430.1543; found, 430.1546.
Synthesis of 15 (Scheme 1C). Intermediates 15a and 15b were
prepared as previously described81,82
Synthesis of (4-(benzyloxy)-2-formylphenyl)boronic Acid Pinacol
Ester (15c). Bis(pinacolato)diboron (0.618 g, 2.43 mmol) (15b), 5-
(benzyloxy)-2-bromobenzaldehyde (0.500 g, 1.71 mmol), and
potassium acetate (0.478 g, 4.82 mmol) were dissolved in 1,4-
dioxane (15 mL); the suspension was then degassed with nitrogen,
after which PdCl2(dppf) (0.119 g, 0.16 mmol) was added. The
reaction mixture was refluxed for 12 h before it was allowed to cool to
room temperature. Solids were then removed by filtration through
Celite washing with EtOAc (100 mL). The filtrate was concentrated
in vacuo and the residue obtained was purified by Teledyne ISCO
CombiFlash automated chromatography (gradient of EtOAc in
hexane, 0−30%) to give a white solid (490 mg, 86%). Purity: >99%
(by HPLC). 1H NMR (300 MHz, chloroform-d): δ 10.69 (s, 1H),
7.90 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 2.5 Hz, 1H), 7.44 (tt, J = 4.0, 2.0
Hz, 2H), 7.41 − 7.37 (m, 3H), 7.22 (dd, J = 8.5, 2.5 Hz, 1H), 5.17 (s,
2H), 1.39 (s, 13H), 1.29 (s, 12H). LCMS (ESI+, m/z): mass not
observed.
Synthesis of Ethyl 2-(5-(Benzyloxy)-1-hydroxy-1,3-dihydrobenzo-
[c][1,2]oxaborol-3-yl)acetate (15d). To a stirred solution of ethyl
acetate (0.32 g, 3.63 mmol, 1.5 equiv) in dry tetrahydrofuran (THF)
was added lithium diisopropylamide (LDA, 3.55 mL, 3.63 mmol, 1.5
equiv, 1 M solution in THF) dropwise at −78 °C. The mixture was
stirred for 30 min at −78 °C before (4-(benzyloxy)-2-formylphenyl)-
boronic acid pinacol ester (0.8 g, 2.36 mmol, 1 equiv) was added.
Next, the reaction mixture was stirred for 2 h at −20 °C before it was
quenched by addition of a saturated solution of NH4Cl (10 mL).
EtOAc (10 mL) was added and the layers were separated. The
aqueous layer was extracted with EtOAc (3 × 10 mL). The combined
organic extracts were washed with brine, dried (MgSO4), and then
concentrated in vacuo. The residue obtained was then purified by
Teledyne ISCO CombiFlash automated chromatography (gradient of
EtOAc in hexane in 0−30%) to give the desired product as a white
solid (160 mg, 57%). Purity >99% (by HPLC). 1H NMR (300 MHz,
methanol-d4): δ 7.62−7.53 (m, 1H), 7.51−7.30 (m, 5H), 7.04−6.97
(m, 2H), 5.53 (dd, J = 8.5, 4.5 Hz, 1H), 5.14 (s, 2H), 4.18 (qd, J =
7.0, 1.5 Hz, 2H), 2.95 (dd, J = 15.5, 4.5 Hz, 1H), 2.55 (dd, J = 15.5,
8.5 Hz, 1H), 1.26 (t, J = 7.0 Hz, 3H). LCMS (ESI+, m/z), 327 [M +
H]+.
Synthesis of 2-(5-(Benzyloxy)-1-hydroxy-1,3-dihydrobenzo[c]-
[1,2]oxaborol-3-yl)acetic Acid (15). To a stirred solution of ethyl
2-(5-(benzyloxy)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)-
acetate (0.3 g, 0.92 mmol, 1 equiv) in THF/H2O (10 mL, 1:1) was
added LiOH·H2O (77 mg, 1.84 mmol, 2 equiv); the mixture was then
stirred for 2 h at room temperature. Water (20 mL) and ethyl acetate
(20 mL) were then added and the layers were separated. The aqueous
layer was acidified to pH 2−3 and then extracted with ethyl acetate (3
× 20 mL). The layers were separated and the combined organic
extracts were washed with brine, dried (MgSO4), and then
concentrated in vacuo. On standing at room temperature overnight,
the product solidified. Further washing with diethyl ether gave the
purified product as a white solid (210 mg, 78%). Purity >97% (by
HPLC).1H NMR (300 MHz, methanol-d4): δ 7.58 (d, J = 8.0 Hz,
1H), 7.49−7.32 (m, 5H), 7.07−6.98 (m, 2H), 5.54 (dd, J = 8.5, 4.5
Hz, 1H), 5.14 (s, 2H), 2.89 (dd, J = 15.5, 4.5 Hz, 1H), 2.51 (dd, J =
15.5, 8.5 Hz, 1H). 13C NMR (151 MHz, DMSO-d6): δ 172.4, 161.4,
158.8, 137.3, 132.2, 128.9, 128.4, 128.4, 115.5, 107.6, 77.3, 69.8, 42.3.
LCMS (ESI+, m/z), 299 [M + H]+.
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